MimiVax and Roswell Park addressing metastatic neuroendocrine tumors
MimiVax Inc. and Roswell Park have initiated a phase 2 clinical trial to assess the safety and efficacy of SurVaxM combined with temozolomide in patients with progressing neuroendocrine tumors, building on promising phase 1 results.
Led by Dr. Jasmeet Kaur at Roswell Park, the trial will compare the safety and effect of temozolomide combined with SurVaxM to temozolomide alone in patients with metastatic NETs that are progressing. SurVaxM is a peptide vaccine that has been shown to produce an immune system response against cancer cells that express the protein survivin and may block the growth of new tumor cells. The new clinical trial builds directly on phase 1 findings from NCT03879694, in which SurVaxM was well tolerated in NET patients and demonstrated measurable clinical benefit with elevated antibody responses.
Roswell Park’s previous NET research demonstrated that survivin, the protein targeted by SurVaxM, is expressed in approximately 52 percent of NET specimens, and that its expression correlates with more aggressive tumor biology and shorter survival.
The initiation of this phase 2 trial comes as MimiVax begins data analysis from its phase 2b SURVIVE trial of SurVaxM in newly diagnosed glioblastoma. SurVaxM is also being evaluated in pediatric brain tumors and multiple myeloma.
